In-vitro antibacterial activity of cefoperazone, a piperazine cephalosporin

Publisher Website
Google Scholar
Abstract
The in-vitro activity of cefoperazone sodium (T-l551) was assessed against clinical isolates of common bacteria. It was active, with more than 90% of isolates sensitive to 8 mg/l of the compound, against enterobacteria. It was also active against Haemophilus influenzae and Neisseria gonorrhoeae, though β-lactamase producers were less sensitive than most isolates of these species. Cefoperazone possessed similar activity to cefotaxime and moxalactam against Pseudomonas aeruginosa with approximately 8-fold higher activity than carbenicillin against most isolates. Like cefotaxime and moxalactam it was active, though less so than cephaloridine, against streptococci and staphylococci, but enterococci and methicillin-resistant staphylococci were resistant. Cefoperazone possessed similar activity to ampicillin but was less active than cefoxitin against Bacteroides fragills, and was less active than ampicillin or cefoxitin against other bacteroides. Cefoperazone was relatively resistant to hydrolysis by most β-lactamases but was readily hydrolysed by the plasmid-mediated TEM-1 enzyme. Most enterobacteria that were relatively resistant to cefoperazone were able to hydrolyse the compound.